论文部分内容阅读
目的观察大环内酯类抗生素阿奇霉素治疗小儿支原体肺炎的临床疗效,并对用药安全性进行评价。方法选择我院2012年6月至2014年10月呼吸科收治的96例小儿支原体肺炎患者,随机平均分为观察组和对照组。观察组给予阿奇霉素治疗,对照组给予红霉素治疗,观察两组的临床疗效和不良反应。结果观察组患者治愈37例,显效8例,无效3例,总有效率为93.75%;对照组治愈30例,显效9例,无效9例,总有效率为81.25%,治疗组疗效优于对照组,差异有统计学意义(P<0.05)。治疗组患者平均退热、止咳、平喘、肺部啰音消失时间均短于对照组,平均住院时间和住院花费均少于对照组,差异有统计学意义(P<0.05)。两组均偶见局部皮疹、注射部分疼痛等轻度不良反应,差异无统计学意义;观察组无胃肠道反应,对照组有4例胃肠道反应。结论阿奇霉素治疗小儿支原体肺炎能有效改善临床症状,较红霉素能提高治疗效果,缩短病程,且无严重不良反应,安全可靠,值得推广应用。
Objective To observe the clinical efficacy of azithromycin as a macrolide antibiotic in the treatment of children with mycoplasma pneumonia and evaluate the safety of medication. Methods A total of 96 children with mycoplasma pneumonia admitted in our department of respiratory department from June 2012 to October 2014 were randomly divided into observation group and control group. The observation group was treated with azithromycin and the control group with erythromycin. The clinical efficacy and adverse reactions of the two groups were observed. Results The observation group of patients cured 37 cases, 8 cases markedly effective, 3 cases were ineffective, the total effective rate was 93.75%; control group cured 30 cases, 9 cases markedly effective, ineffective in 9 cases, the total effective rate was 81.25% Group, the difference was statistically significant (P <0.05). The mean fever, cough, asthma, and pulmonary rales disappeared in the treatment group were shorter than those in the control group. The average length of stay and hospitalization were less in the treatment group than in the control group (P <0.05). Two groups were occasionally partial rash, injection of some pain mild adverse reactions, the difference was not statistically significant; observation group without gastrointestinal reactions, the control group, 4 cases of gastrointestinal reactions. Conclusion Azithromycin treatment of children with mycoplasma pneumonia can effectively improve clinical symptoms, more effective than erythromycin in treatment, shorten the course of the disease, and no serious adverse reactions, safe and reliable, it is worth promoting the application.